Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

E-Newsletter

  • Subscribe to our e-Newsletter to receive email updates:

  • Related Articles

    Most Recent

    Archives

    Join Us

    News: Home Page Latest News

    VICC research efforts in spotlight at AACR conference

    Thursday, April 30th, 2015

    Adding an investigational drug to an already approved estrogen blocking therapy appears to be safe and provided clinical benefit for some postmenopausal women with estrogen-positive breast cancer. The research led by Ingrid Mayer, M.D., associate professor of Medicine and clinical director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), was selected for the […]

    Statin use improves renal cell cancer survival

    Friday, April 17th, 2015

    A new study led by Vanderbilt University investigators found that patients being treated with statins at the time of surgery for kidney cancer, also known as renal cell carcinoma, had improved overall survival and disease-specific survival. Drugs known as statins are widely used to lower cholesterol and previous studies have indicated that they could be […]

    NCI report shows U.S. cancer deaths on decline

    Thursday, April 2nd, 2015

    The death rates for most forms of cancer continue to decline at a modest pace among men, women and children in the United States, according to the Annual Report to the Nation on the Status of Cancer 1975 – 2011. The report from the National Cancer Institute, a division of the National Institutes of Health, […]

    VICC’s Johnson to study cancer survivorship with immune inhibitor drugs

    Thursday, March 19th, 2015

    Douglas Johnson, M.D., assistant professor of Medicine, has been named a recipient of the National Comprehensive Cancer Network  (NCCN) Foundation Young Investigator Awards. The two-year grant will provide $150,000 in funding for his research on survivorship among cancer patients who receive drugs called immune checkpoint inhibitors. The formal announcement of the grant awardees was made […]

    Barocas named to Commission on Cancer

    Thursday, March 12th, 2015

    Daniel Barocas, M.D., MPH, assistant professor of Urologic Surgery at Vanderbilt University Medical Center, was recently named a representative on the Commission on Cancer. The program helps to raise the quality of care at hospitals across the country through developing standards for cancer care and uses those standards to accredit hospitals. Barocas will represent the […]

    Grant boosts head and neck lymphedema research

    Monday, March 9th, 2015

    Vanderbilt University School of Nursing (VUSN) has been awarded a four-year, $2.4 million grant from the National Institutes of Health/National Institute of Dental and Craniofacial Research to establish a valid, clinically useful measurement battery for head and neck lymphedema and fibrosis (LEF). Principal investigator Jie Deng, Ph.D., R.N., developed the proposal because she commonly sees […]

    MDS patient and family forum March 14

    Monday, March 2nd, 2015

    The Myelodysplastic Syndrome Foundation, Inc., is sponsoring a patient and caregiver forum on March 14, 2015 at the Marriott Nashville at Vanderbilt. The forum will feature a presentation and Q&A session with Vanderbilt-Ingram Cancer Center’s Michael Savona, M.D., about new therapies and treatment options for MDS. The conference runs from 9:30 a.m. to 2:00 p.m. and will also […]

    ‘Stretched’ cells promote cancer

    Thursday, February 26th, 2015

    Interactions between tumor cells and other cell types in the surrounding microenvironment (stroma) are crucial for tumor cell growth, survival and metastatic spread. Although tumor cells are known to induce mechanical changes in their microenvironment, few studies have examined the effect of mechanical stimuli on stromal cells such as fibroblasts. Donna Webb, Ph.D., Deyu Li, […]

    Gene profile predicts metastasis

    Thursday, February 12th, 2015

    Gene expression profiling has been applied to predict metastatic recurrence, the leading cause of deaths in patients with colorectal carcinoma. However, the biological mechanism is not completely understood, driving poor clinical outcomes. To address this issue, Dan Beauchamp, M.D., Bing Zhang, Ph.D., and colleagues analyzed the 11 human microarray datasets from 1,295 tumor specimens as […]

    Grant bolsters pancreatic cancer drug discovery

    Thursday, January 29th, 2015

    The Lustgarten Foundation has awarded a $1.5 million Research Investigator Grant to Stephen Fesik, Ph.D., professor of Biochemistry, Pharmacology and Chemistry, for research designed to discover new drugs for the treatment of pancreatic cancer. This is Fesik’s second three-year award from the Lustgarten Foundation in support of his research targeting K-Ras, a protein mutated in […]

    Next Page »« Previous Page